Clinical Trials in Cancer
Summary
SMi’s Clinical Trials in Cancer conference will provide up-to-date information on the current challenges in clinical development, with an insight into European and US regulatory requirements. Attendees will benefit from presentations on key novel therapies currently in development and how they are being integrated into clinical trials. Don't miss this opportunity to meet experts in the field as they discuss how anti-cancer drug development can be optimised and carried forward to achieve the uSMi’s Clinical Trials in Cancer conference will provide up-to-date information on the current challenges in clinical development, with an insight into European and US regulatory requirements. Attendees will benefit from presentations on key novel therapies currently in development and how they are being integrated into clinical trials.
Don't miss this opportunity to meet experts in the field as they discuss how anti-cancer drug development can be optimised and carried forward to achieve the ultimate aim of getting effective drugs to the market faster!
To view the full conference programme OR to book your place simply visit: www.smi-online.co.uk/ctcancer5.asp
Alternatively contact James Kennedy on tel: +44 (0) 20 7827 6186 or
email:jkennedy@smi-online.co.uk
Discounts are also available for group bookings.
An unique opportunity to learn from leading industry experts, including:
- Dr Pearl Huang, Vice President, Biology, Oncology & Proliferative Disease, MMPD CEDD, GlaxoSmithKline
- Dr Andrew Hughes, Director, Discovery Medicine, Cancer & Infection, AstraZeneca
- Dr Peter Wyld, Director, Oncology Development & EU Therapeutic Area Specialist, Amgen
- Dr Anne Blackwood-Chirchir, Clincal Discovery, Oncology, Bristol-Myers Squibb
- Dr Doriano Fabbro, Senior Unit Head, Expertise Platform Kinases & Head, Kinase Biology & Technologies , Novartis
- Andrew Stone, Statistical Science Director, AstraZeneca
- Dr Michael Lahn, Medical Advisor, Eli Lilly
- Dr Iman El-Hariry, Senior Director, Oncology Medicines Centre, GlaxoSmithKline
- Professor Karol Sikora, Professor, Cancer Medicine, Imperial College & Scientific Director, Medical Solutions
Key issues that will be addressed at the Conference include:
- COMPOUND DRUG CASE STUDIES: Discover new drugs currently being developed in phases I-III by major companies in the industry
- TISSUE BIOMARKERS IN CANCER DRUG DEVELOPMENT: Hear discussions on new technologies being applied in clinical trials from patient selection to clinical pharmacology
- REGULATORY APPROVAL: Learn how regulations from Europe and the US are affecting clinical trials and how to develop the necessary protocols to meet them
- DESIGNING CLINICAL TRIALS PHASES I-III: Discover how to increase efficiency, and satisfy regulations, ethical standards and ensure GMP/GCLP compliance
- NOVEL THERAPIES: Learn from recognised experts as they discuss how novel therapies are being integrated into clinical trials through case study examples
NETWORKING OPPORTUNITIES: Meet the leaders in the field, make valuable contacts and learn from their experience and expertise
